|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings also suggest that MTHFD2 and HIF-2α form a positive feedforward loop in RCC, promoting metabolic reprograming and tumor growth.
|
31289360 |
2019 |
|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A small molecule inhibitor that binds to HIF-2α and blocks dimerization with HIF-1β is in clinical trials for the treatment of renal cell carcinoma.
|
30625281 |
2019 |
|
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our study confirmed sex-specific associations for two known RCC risk loci at 14q24.2 (DPF3) and 2p21(EPAS1).
|
31231134 |
2019 |
|
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Sex specific associations in genome wide association analysis of renal cell carcinoma.
|
31231134 |
2019 |
|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
While HIF1α can act as a ccRCC tumor suppressor, HIF2α has emerged as the key HIF isoform that is essential for ccRCC tumor progression.
|
29938199 |
2018 |
|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Knockdowns of TRAIL averted apoptotic cell death caused by HIF2-alpha inhibition in starvation-resistant RCCs.
|
29796174 |
2018 |
|
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
|
28951458 |
2017 |
|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
New treatment modalities targeted to HIF-1α and HIF-2α might be planned as well as VEGF-targeted therapies in the management of clear cell renal cell carcinomas.
|
27583351 |
2017 |
|
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
HIF2A germline-mutation-induced polycythemia in a patient with VHL-associated renal-cell carcinoma.
|
29172931 |
2017 |
|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We found that the anti-angiogenic TKI sunitinib disrupted the balance between HIF-1α and HIF-2α in RCCs and led to a protective effect on HUVECs against sunitinib treatment when cultured with conditioned medium.
|
28572533 |
2017 |
|
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies multiple risk loci for renal cell carcinoma.
|
28598434 |
2017 |
|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cell culture metabolomics analysis was utilized to determined effect of VHL and HIF-1α or HIF-2α on metabolism of renal cell carcinomas (RCC).
|
26620126 |
2016 |
|
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations in HIF2A have been reported in PPGLs associated with polycythemia, which have been reported to also be present in patients with RCCs and HBs.
|
26514359 |
2016 |
|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signaling may promote renal cell carcinoma (RCC) progression via altered HIF-2α/VEGF signaling.
|
27848972 |
2016 |
|
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We show that DNA-PKcs over-expression regulates mTORC2-AKT activation, HIF-2α expression and RCC cell proliferation.
|
27412013 |
2016 |
|
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The authors observed evidence of interactions between PhIP and RCC susceptibility variants in 2 genes: inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) (rs718314; multiplicative P for interaction = .03 and additive P for interaction =.002) and endothelial PAS domain-containing protein 1 (EPAS1) (rs7579899; additive P for interaction =.06).
|
26551148 |
2016 |
|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Together, these results may provide us a new therapeutic approach via targeting this newly identified signal from LncRNA-SARCC to AR-mediated HIF-2α/C-MYC signals against RCC progression.
|
26973243 |
2016 |
|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Herein, we provide mechanistic evidence that HIF-2α can be degraded in cytoplasm under hypoxic conditions via the 26S proteasome and that MDM2 is the E3 ligase which induces the hypoxic degradation of HIF-2α in PI-3K-dependent manner in VHL-deficient RCC cells.
|
25578041 |
2015 |
|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma.
|
26439684 |
2015 |
|
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer.
|
25826619 |
2015 |
|
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our data provide insight into the link between HIF2α, the ITPR1-related pathway, and natural immunity and strongly suggest a role for the HIF2α/ITPR1 axis in regulating RCC cell survival.
|
25297632 |
2014 |
|
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we demonstrate that peroxisome abundance is reduced in VHL-deficient human clear cell renal cell carcinomas with high HIF-2α levels.
|
25440060 |
2014 |
|
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
|
24189146 |
2014 |
|
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We find that DDT expression mirrors MIF expression in ccRCC tumor sections with high correlation and that, mechanistically, DDT is a novel hypoxia-inducible gene and direct target of HIF1α and HIF2α.
|
24356968 |
2014 |
|
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In determining the critical functions for HIF2α expression in RCC cells, the NADPH oxidase NOX4 has been identified, but the pathogenic contributions of NOX4 to RCC have not been evaluated directly.
|
24755467 |
2014 |